RedHill Biopharma Ltd. announced the acquisition of exclusive global commercialization rights to Rebyota® and exclusive U.S. commercialization rights to Clenpiq® from Ferring Pharmaceuticals via a License and Commercial Supply Agreement. The transaction includes an upfront payment of $12 million, tiered royalties ranging from 5% to 20%, and potential sales milestones. RedHill funded the upfront cost through the previously announced $18 million divestiture of its Talicia® product. Rebyota generated approximately $16.9 million in U.S. net sales in 2025, while Clenpiq generated $20.6 million, bringing total combined 2025 net sales to roughly $37.5 million. The agreement features a 13-year initial term with automatic two-year renewals and requires minimum annual purchase commitments for Rebyota from 2027 through 2029. RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology.

RedHill Biopharma Ltd. announced the divestment of its Talicia business to a subsidiary of Apotex Health Corp. for an upfront payment of $18 million plus up to $35 million in potential worldwide net sales milestone payments. The transaction involves RedHill selling its 70% interest in Talicia Holdings Inc., while Apotex retains the remaining 30% acquired from Cumberland Pharmaceuticals. RedHill entered into a five-year non-compete covenant and a six-month Transition Services Agreement with an option to extend for three months. This strategic move aims to generate immediate capital, strengthen liquidity, and fund future commercial expansion in gastrointestinal diseases, infectious diseases, and oncology.

RedHill Biopharma provided an update on the development of opaganib for Ebola virus disease amid a Bundibugyo ebolavirus outbreak with 3,221 cases and 1,407 deaths. The company is finalizing development next steps and engaging in potential partnership discussions with the African Medicines Agency, the Ugandan Ministry of Health, Mbarara University of Science and Technology, and the DRC Scientific Advisory Committee. Opaganib is being evaluated as a host-directed antiviral add-on to remdesivir, supported by Phase 3 COVID-19 data showing a 70.2% mortality reduction and preclinical studies demonstrating synergistic effects. RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology.

RedHill Biopharma rescheduled its annual general meeting from July 28, 2026, to August 6, 2026, to include an additional proposal. Shareholders will vote on re-appointing Kesselman & Kesselman as auditors, re-electing directors Rick D. Scruggs and Dr. Shmuel Cabilly for three-year terms, and approving the engagement of Dror Ben-Asher as both Chairman and CEO for three years starting August 6, 2026. Additionally, the company proposes amending its Articles of Association to eliminate the par value of its shares to increase administrative flexibility. The record date for voting is July 2, 2026. The company operates in the biopharmaceutical industry and develops therapeutic drugs.